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Vitamin D deficiency has been linked to cardiovascular
disease and early mortality in patients on hemodialysis;
however, it is not known if the same association exists at
earlier stages of chronic kidney disease. To determine this we
enrolled 168 consecutive new referrals to a chronic kidney
disease clinic over a 2 year period and followed them for up
to 6 years. All patients were clinically stable and had an
estimated glomerular filtration rate (eGFR) at stage 2 or less
and were without an imminent need for dialysis. Baseline 25-
hydroxyvitamin D levels directly and significantly correlated
with eGFR. After an average follow-up of 48 months, 48
patients started dialysis and 78 had died. In crude analyses,
25-hydroxyvitamin D predicted both time to death and end-
stage renal disease. A dual-event Cox’s model confirmed
25-hydroxyvitamin D as an independent predictor of study
outcomes when adjusted for age, heart failure, smoking,
C-reactive protein, albumin, phosphate, use of converting
enzyme inhibitors or angiotensin receptor blockers, and
eGFR. Our study shows that plasma 25-hydroxyvitamin D is
an independent inverse predictor of disease progression and
death in patients with stage 2–5 chronic kidney disease.
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Vitamin D (VD) is a fundamental micronutrient with major
implications for human health.1 On a world scale, about one
billion people have VD deficiency or insufficiency (defined as
25-hydroxy-vitamin D (25D) levels o30 and o15 ng/ml,
respectively). At community level over 50% of American and
European elderly men and women have clear-cut VD
insufficiency or deficiency. Although this vitamin is mainly
seen as a compound pivotal for bone physiology, it is also
central to optimal functioning of other organ systems
including the cardiovascular (CV), endocrine, and immune
systems. Mild to moderate VD deficiency is associated with
cancer, hypertension, diabetes, and heart failure.1 Pleiotropic
effects of VD are of relevance to patients with chronic kidney
disease (CKD), particularly to those with end-stage renal
disease (ESRD), a population where VD insufficiency and/or
low levels of the active form 1,25-di-hydroxylated-VD
(1,25D) is an almost universal finding.2 Alterations in the
immune response,3,4 insulin resistance,5,6 vascular function,7
and cardiomyopathy8,9 are all well documented clinical
correlates of VD deficiency in these patients. A role of VD
deficiency in the short life expectancy of ESRD is supported
by a series of observational studies showing that paracalci-
tol,10–12 1,25D,13 and 1a-hydroxylated-VD14 treatment is
associated with better survival in this population. However,
observational and mechanistic studies — no matter how
rigorously conducted — still constitute an insufficient proof
that VD directly impacts on CKD outcomes.15–16 Although
the controlled clinical trial is the ultimate test of hypothesis,
prospective cohort studies investigating the quantitative
association of VD status with clinical outcomes accounting
for time-varying confounders may advance our knowledge
on the role of VD deficiency in these populations. To date
there is only one study in ESRD patients2 testing the
association between the storage form 25D and the active
form 1,25D with 90-day mortality, but the issue has never
been explored in predialysis patients and in long-term
studies. Focusing on the CKD population appears important
for at least three reasons. First, because the risk profile of
mild to severe CKD substantially differs from that of ESRD.17
Second, because the severity of VD deficiency may proceed in
parallel with renal function loss.18 Third, because there is
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circumstantial evidence that such a deficiency may contribute
to renal disease progression.19
In this study we modeled by a competing risk approach
the relationship of VD with progression to ESRD and death
in a well-characterized incident cohort of VD naı¨ve, stages
2–5 CKD patients. The results of this study indicate that low
levels of the storage form of VD before VD supplementation,
signals a relatively higher risk for dialysis and death from all
and CV causes in this patient population.
RESULTS
Patient characteristics
At enrollment the study population (Table 1) had an average
age of 70.1±11.9 years, 63% of the patients were male,
26% had diabetes, and 58% had background CV complica-
tions. All subjects were Caucasian and no subject had
abnormal liver enzymes or cirrhosis. Patient distribution by
CKD stage was: 9.5% in stage 2; 40.5% in stage 3, 40.5% in
stage 4; and 9.5% in stage 5. Over 60% of the study sample
had parathyroid hormone (PTH) levels 465 pg/ml. The
median value of plasma levels of 25D was 18.1 ng/ml
(interquartile range: 13–26 ng/ml), and that of 1,25D was
18.5 pg/ml (13–27.5 pg/ml). The proportions of patients with
25D o30 and o15 ng/ml (the thresholds for VD insuffi-
ciency and deficiency states20) by CKD stage were: 62%
(10 of 16) and 25% (4 of 16, stage 2); 79% (54 of 68) and
29% (20 of 68, stage 3); 85% (58 of 68) and 37% (25
of 68, stage 4); and 88% (14 of 16) and 56% (9 of 16, stage 5).
After baseline assessment, as per center policy, the vast
majority (90%) of patients with PTH levels 4100 pg/ml
were started on 1,25D treatment, whereas only 16% of the
patients with PTHo100 received calcitriol. Conversely the
proportion of patients who were started on calcitriol
supplements was similar by 25D status (X15 ng/ml:
21%; o15 ng/ml: 22%). At no stage of follow-up patients
were prescribed cholecalciferol or other forms of VD except
1,25D.
Baseline correlates of vitamin D
At baseline both 25D and 1,25D were associated with
estimated glomerular filtration rate (eGFR) (r¼ 0.22,
P¼ 0.003; and r¼ 0.46, Po0.001) (Figure 1; Table 2). 25D
and 1,25D were significantly interrelated (r¼ 0.41, Po0.001)
and both correlated directly with calcium levels and male
gender, and inversely with age, diabetic status, CV disease,
phosphate (Table 2), and PTH (Figure 2). 25D correlated
with PTH more strongly than did 1,25D (r¼0.42,
Po0.001 vs r¼0.17, P¼ 0.038).
Table 1 | Main clinical characteristics and baseline data by vitamin D status
All 25D o15 ng/ml 25D X15 ng/ml
N=168 N=58 N=110 P-value
Age (years) 70.1±11.9 72.9±9.9 68.5±12.6 0.012
Body mass index (kg/m2) 26.8±4.9 26.1±4.7 26.1±4.7 0.247
Male gender 106 (63.1%) 26 (45%) 80 (72%) o0.001
Diabetics 43 (26%) 20 (34%) 23 (21%) 0.055
Smoking habit 55 (32%) 16 (27%) 39 (35%) 0.301
Malignancy 20 (12%) 10 (17%) 10 (9%) 0.121
Presence of CV diseases 96 (57%) 39 (67%) 57 (52%) 0.055
Coronary artery disease 56 (34%) 23 (39%) 33 (30%) 0.207
Peripheral–vascular disease 48 (28%) 19 (33%) 29 (26%) 0.383
Cerebral–vascular disease 43 (26%) 19 (33%) 24 (22%) 0.122
Heart failure 43 (26%) 21 (36%) 22 (20%) 0.022
Serum creatinine (mg/100 ml) 2.3±1.2 2.5±1.2 2.3±1.1 0.331
eGFR (ml/min/1.73 m2) 33.5±16.9 30±16 35±17 0.045
CKD stage 2 (eGFR 60–89) 16 (9.5%) 4 (7%) 12 (11%) 0.178
CKD stage 3 (eGFR 30–59) 68 (40.5%) 20 (34%) 48 (44%)
CKD stage 4 (eGFR 15–29) 68 (40.5%) 25 (43%) 43 (39%)
CKD stage 5 (eGFR o15) 16 (9.5%) 9 (16%) 7 (6%)
Urinary protein (g/24 h) 0.41 (0.11–1.93) 0.45 (0.12–1.95) 0.41 (0.11–1.93) 0.259
Calcium (mg/100 ml) 9.4±0.6 9.3±0.6 9.4±0.6 0.114
Phosphate (mg/100 ml) 3.4±0.8 3.6±0.9 3.3±0.8 0.034
PTH (pg/ml) 116±114 154±144 96.1±89 0.006
Hemoglobin (g/100 ml) 12.8±1.5 12.3±1.4 13.1±1.6 o0.001
Total cholesterol (mg/100 ml) 209±49 199±52 213±48 0.083
Albumin (g/100 ml) 3.8±0.6 3.8±0.6 3.9±0.5 0.416
C-reactive protein (mg/l) 7.1±9.8 7.5±8.6 6.9±10.4 0.674
Fibrinogen (mg/100 ml) 428±115 444±127 420±107 0.219
Homocysteine (mmol/l) 27.1±17.1 26.9±14.5 27.2±18.4 0.912
25D, 25-hydroxy-vitamin D; eGFR, MDRD glomerular filtration rate estimate; CKD, chronic kidney disease; PTH, parathyroid hormone; CV, cardiovascular.
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Survival data
During the study period (mean follow-up 48 months;
median 57, range 1.5, 72) 48 patients progressed to dialysis
(7.2 events per 1000 patient-years, 95% CI 5.4, 9.6) and 78
died (52 for CV events, 14 for malignancies or cachexia and
12 for infectious diseases), 21 of whom after starting dialysis
(9.8 deaths per 1000 patient-years, 95% CI 7.8, 12.2).
In crude analyses based on baseline values both 25D
(Figure 3) and 1,25D were inverse predictors of death
(Po0.001 and P¼ 0.002) and progression to ESRD (both
Po0.001). eGFR decline, proteinuria, and all markers of
CKD (Hb, Ca, P and their product and PTH) were associated
with the risk of both dialysis and death (Pp0.002). Serum
albumin and C-reactive protein were associated with
mortality (Pp0.002), fibrinogen with both events
(Po0.001), and homocysteine with the risk for dialysis
initiation (P¼ 0.014). Analyses based on unadjusted time-
varying covariates were similar.
Table 3 shows the predictive power of 25D (either
expressed as a continuous or as a categorical variable) for
death, ESRD, and for double event (death/ESRD) from
models based on time-independent or on time-dependent
variables. The effect of 25D did not change by presence of
diabetes, subsequent VD therapy, and age or across CKD
stages or levels of PTH or proteinuria. Models based on time-
independent variables adjusted for treatment (model 6) did
not satisfy the proportionality assumption, which was instead
satisfied in corresponding models including time-varying
covariates.
The use of updated rather than baseline eGFR, proteinuria
and other laboratory covariates values, and therapies
improved the fit of the models. No correlate of eGFR decline
(hemoglobin, calcemia, calcium/phosphate product, PTH,
and 1,25D) maintained a significant effect on either the risk
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Figure 1 | Distribution of 25-hydroxy-vitamin D (25D, gray)
and 1,25-di-hydroxy-vitamin D (1,25D, white) by tertile of
glomerular filtration rate at baseline.
Table 2 | Correlations of baseline clinical characteristics,
markers of nutrition, mineral metabolism, and renal function
with levels of serum 25D and 1,25D
25D 1,25D
r P-value r P-value
Age 0.24 0.001 0.24 0.002
Male gender 0.18 0.021 0.18 0.021
Diabetic 0.21 0.006 0.21 0.007
Malignancy 0.11 0.134 0.05 0.464
Cardiovascular disease 0.15a 0.047 0.09 0.225
Log-albumin 0.15a 0.050 0.19a 0.019
Log-C-reactive protein 0.19 0.013 0.13 0.109
eGFR 0.22 0.003 0.4615 o0.001
Urinary protein 0.20 0.010 0.30 o0.001
Calcium 0.16 0.038 0.07 0.388
Phosphate 0.11 0.132 0.27 o0.001
Log-PTH 0.41a o0.001 0.16a 0.038
Log-25D — — 0.41 o0.001
25-D, 25-hydroxyvitamin D; 1,25D, 1,25-di-hydroxy-vitamin D; eGFR, glomerular
filtration rate estimate; PTH, parathyroid hormone; r, correlation coefficient.
aIndicates log-values of VD.
Bold entries highlight significant correlations.
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Figure 2 | Relationships among 1,25-di-hydroxy-vitamin D
(1,25D), 25-hydroxy-vitamin D (25D) and parathyroid
hormone (PTH). PTH and 25D had positively skewed distributions
and were log transformed (see values in parentheses). The
corresponding untransformed values are also given.
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Figure 3 | Crude renal and patient survival curves by presence of 25D deficiency (levels of 25D o15 vs 15 ng/ml or greater).
Table 3 | Regression models of time to single and dual events (dialysis or death) as a function of 25-hydroxy-vitamin D levels at
baseline
HR (95% CI) per 10 ng/ml of 25D HR (95% CI) X vs o15 ng/ml of 25D
T-independent T-dependent T-independent T-dependent
(A) Models of renal survival (event N=48)
(1) Unadjusted 0.53 (0.35, 0.78) 0.53 (0.35, 0.78) 0.46 (0.26, 0.81) 0.46 (0.26, 0.81)
(2) Age, gender, BMI, SMK, season 0.45 (0.28, 0.72) 0.45 (0.28, 0.72) 0.50 (0.27, 0.93) 0.50 (0.27, 0.93)
(3) Diabetes, cancer, CVD, PAD, CAD, heart failure 0.43 (0.27, 0.68) 0.43 (0.27, 0.68) 0.48 (0.26, 0.89) 0.48 (0.26, 0.89)
(4) ALB, CRP, fibrinogen, Hcy 0.39 (0.24, 0.65) 0.40 (0.24, 0.66) 0.44 (0.24, 0.79) 0.43 (0.24, 0.79)
(5) Proteinuria, GFR, Ca/P, 1.25D, Hb 0.52 (0.31, 0.86) 0.58 (0.37, 0.91) 0.50 (0.26, 0.98) 0.57 (0.31, 1.00)
(6) CEI/ARB, ESA, VDT 0.49 (0.32, 0.77)w 0.44 (0.28, 0.69) 0.67 (0.36, 1.22)w 0.53 (0.29, 0.96)
*Final (proteinuria, GFR, P, CEI/ARB) 0.58 (0.36, 0.93) 0.57 (0.36, 0.89) 0.51 (0.26, 0.97) 0.48 (0.26, 0.90)
(B) Models of patient survival (event N=78)
(1) Unadjusted 0.60 (0.45, 0.80) 0.60 (0.45, 0.80) 0.43 (0.28, 0.68) 0.43 (0.28, 0.68)
(2) Age, gender, BMI, SMK, season 0.59 (0.40, 0.86) 0.59 (0.40, 0.86) 0.53 (0.31, 0.89) 0.53 (0.31, 0.89)
(3) Diabetes, cancer, CVD, PAD, CAD, heart failure 0.70 (0.51, 0.95) 0.70 (0.51, 0.95) 0.58 (0.36, 0.93) 0.58 (0.36, 0.93)
(4) ALB, CRP, fibrinogen, Hcy 0.55 (0.40, 0.77) 0.61 (0.44, 0.83) 0.42 (0.26, 0.67) 0.47 (0.29, 0.76)
(5) Proteinuria, GFR, Ca/P, 1.25D, Hb 0.63 (0.46, 0.86) 0.58 (0.40, 0.83) 0.50 (0.30, 0.86) 0.41 (0.24, 0.70)
(6) CEI/ARB, ESA, VDT 0.57 (0.42, 0.78)w 0.58 (0.43, 0.78) 0.45 (0.29, 0.72)w 0.45 (0.28, 0.71)
*Final (age, heart failure, SMK, CRP, ALB, P, CEI/ARB) 0.72 (0.51, 1.00) 0.76 (0.56, 1.05) 0.59 (0.35, 0.98) 0.61 (0.36, 1.00)
(C) Double event models (event N=126)
(1) Unadjusted 0.54 (0.43, 0.74) 0.54 (0.43, 0.74) 0.42 (0.29, 0.60) 0.42 (0.29, 0.60)
(2) Age, gender, BMI, SMK, season 0.56 (0.43, 0.73) 0.52 (0.38, 0.70) 0.49 (0.33, 0.72) 0.52 (0.34, 0.78)
(3) Diabetes, cancer, CVD, PAD, CAD, heart failure 0.55 (0.42, 0.71) 0.55 (0.42, 0.71) 0.50 (0.34, 0.72) 0.50 (0.34, 0.72)
(4) ALB, CRP, fibrinogen, Hcy 0.46 (0.35, 0.61) 0.53 (0.40, 0.71) 0.40 (0.28, 0.58) 0.46 (0.31, 0.67)
(5) Proteinuria, GFR, Ca/P, 1.25D, Hb 0.58 (0.45, 0.75) 0.61 (0.47, 0.79) 0.58 (0.38, 0.89) 0.50 (0.33, 0.86)
(6) CEI/ARB, ESA, VDT 0.52 (0.40, 0.67)w 0.54 (0.42, 0.71) 0.50 (0.34, 0.72)w 0.49 (0.33, 0.71)
*Final (proteinuria, age, heart failure,
SMK, CRP, ALB, P, CEI/ARB, GFR)
0.65 (0.50, 0.85) 0.69 (0.53, 0.90) 0.57 (0.38, 0.84) 0.56 (0.39, 0.82)
1,25D, 1,25-di-hydroxy-vitamin D levels; ALB, serum albumin; BMI, body mass index; CAD, coronary artery disease; Ca/P, calcium, phosphate, and their product; CEI/ARB,
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; CI, confidence interval; CVD, cerebrovascular disease; CRP, C-reactive protein; ESA, erythropoiesis
stimulating agents; GFR, estimated glomerular filtration rate; Hb, hemoglobin; Hcy, homocysteine; HR, hazard ratio; PAD, peripheral artery disease; SMK, current or past
smoking habit; VDT, calcitriol supplements.
HR (95% CI) summarizing the effect of 10 ng/ml increase in the levels of 25-hydroxy-vitamin D (left columns) or the effect of levels of 25D equal to 15 ng/ml or greater vs less
(right columns). T-independent: models built on baseline values of the covariates; T-dependent: models built on values updated over follow-up time. Models in A and B are
time to single-event models; models in C are competing risks models. Models 1 include the exposure only. Models 2–6 include additional sets of variables. The fit was worse
for all T-independent models and some (w) clearly violated the proportionality assumption. Final models (*) were built as described in the ‘Materials and Methods’ section.
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for dialysis or death when eGFR was taken into account, with
the exception of phosphate levels and 25D.
Figure 4 summarizes the final competing risk model of
dialysis and death. The model is stratified by event type and
eGFR tertiles (o20, 20–40, and 440 ml/min). Baseline levels
of 25D (10 ng/ml increase) were associated with longer renal
and patient survival (HR 0.69, 95% CI 0.53, 0.90). The effect
of 25D was materially the same when eGFR was entered as
covariate in the model (HR 0.71, 95% CI 0.57, 0.89), but the
overall model fit was worse. The effects of 25D, phosphate
and use of converting enzyme inhibitors or angiotensin
receptor blockers were the same for both events. Proteinuria
had a significant effect on the risk for dialysis only. Age,
history of heart failure, smoking habit, C-reactive protein,
and serum albumin levels had a specific effect on mortality.
No significant effect was associated with calcitriol prescrip-
tion and other covariates, or potential effect modifiers.
Results of the model of dialysis and death from CV causes
were similar with a slightly smaller effect of 25D (HR 0.77,
95% CI 0.59, 0.99) and greater effect of phosphate (HR 1.84,
95% CI 1.41, 2.40).
DISCUSSION
This study shows that vitamin D deficiency is common in
patients with CKD stages 2–5, that the levels of both the
storage form and the active form of VD decrease as eGFR
declines, and for the first time links the levels of the storage
form of VD to the risk of progression to dialysis, CV events,
and death in this patient population.
VD insufficiency and deficiency in CKD
The prevalence of VD deficiency in the general population is
considerable and varies by race, sunlight exposure, and
presence of risk factors such as age, type-2 diabetes and
obesity, and other comorbidities.1 In our old, ethnically
homogeneous cohort the prevalence of 25D insufficiency and
deficiency increased from 62 and 25% in stage 2 to 88 and
56% in stage 5, a figure even greater than recently reported in
hemodialysis patients.2 The age frame of our old cohort,
which reflects the typical CKD population referred to
European Renal units,21 is most likely implicated in such a
high prevalence. In addition, we found that low 25D was
related to diabetes and female gender. However, we believe
25D (10 ng/ml) (0.69; 0.53, 0.90)
Phosphate (mg/100 ml) (1.57; 1.22, 2.02)
CEI/ARB (Yes vs. No) (0.52; 0.36, 0.76)
Proteinuria (1–2 vs. < 1 g) (1.90; 0.65, 5.57)
Proteinuria (≥ 2 vs. < 1 g) (3.80; 1.24, 11.61)
Age (per year) (1.03; 1.01, 1.06)
Heart failure (Yes vs. No) (1.60; 0.99, 2.60)
Smoking (Yes vs. No) (2.43; 1.56, 3.78)
CRP (mg/l) (1.02; 1.01, 1.03)
SAlbumin (<4 g/100 ml) (1.89; 1.06, 3.37)
0.50 1.00 1.50 2.00 2.50 3.00 3.50
Hazard ratio
Prognostic factors for both ESRD and death
Prognostic factors specific for ESRD
Prognostic factors specific for death
Variables in the equation (HR; 95%CI)
4.000.10
(5.57)
4.50 5.00
(11.61)
Figure 4 | Hazard ratios (HRs) and 95% confidence intervals (95% CI) for dialysis and death associated with the covariates in the
final competing risk model (Table 3). The model is stratified by event type and eGFR tertile (o20, 20–40, 440 ml/min). The specific effect
of each covariate on each study outcome is reported in the figure. Baseline levels of 25-hydroxy-vitamin D (10 ng/ml increase), time-varying
use of converting enzyme inhibitors or angiotensin receptors blockers (CEI/ARB), and time-varying values of phosphate affected both risks
(dialysis and death); time-varying daily proteinuria values (1–2 g vs o1 and 42 vs o1 g/day) had a dialysis-specific effect; age, smoking
habit, history of heart failure, and time-varying values of C-reactive protein (mg/l) and serum albumin (o4 vs X4 g/100 ml) had a specific
effect on patient mortality.
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that these factors still constitute an incomplete explanation
for the exceedingly high prevalence and severity of 25D
deficiency observed in CKD. 25D synthesis depends on the
bioavailability of the cutaneous precursor cholecalciferol and
the 25-hydroxylation by the liver. Although 25D deficiency is
considered as a feature of CKD in current guidelines,20 to
date there is only one study performed in hospitalized
patients indicating that CKD is a risk factor 25D deficiency.22
Neither the study by Wolf et al.,2 nor our study included a
general population sample allowing a formal comparison of
CKD patients with an appropriately matched control group.
Yet the pervasiveness of the phenomenon in these studies is
such that it appears unlikely it solely be due to confounding
by comorbidities, inadequate intake, aging, and risk factors
other than renal insufficiency. The cutaneous photoproduc-
tion of cholecalciferol, the 25D precursor molecule, is known
to be compromised in uremia.23 Observations made in the
Third National Health and Nutrition Examination Survey
(NHANES III) database demonstrated that a graded relation-
ship exists between serum 25D and proteinuria even at
subnephrotic levels.24 Therefore CKD may be a risk factor for
25-VD deficiency and this phenomenon may depend on
these kidney-specific and other still unknown mechanisms.
However generated, low 25D levels may disturb important
biological control systems including PTH synthesis. Recent in
vitro studies in bovine parathyroid cells have indeed shown
that these cells are endowed with 1a-hydroxylase activity and
that may locally synthesize 1,25-VD. This suggests that
circulating 25D in CKD patients may have a more relevant
role in PTH regulation than previously recognized.25 Accord-
ingly, we found that circulating levels of these vitamins were
strongly associated to each other. This observation is
compatible with the hypothesis that under normal conditions
the highly efficient production of 1,25D by the kidney may
ensure adequate synthesis of the active hormone even in 25D
depleted subjects.26 Conversely, 1,25D production may
become critically dependent on 25D availability in CKD due
to the deficient 1a-hydroxylase activity.
VD and clinical outcomes
The main finding of the present study is that 25D levels
predict progression to dialysis and death over a long-term
follow-up (median 48 months). In our analyses we
considered not only comorbidities and traditional risk factors
but also risk factors of peculiar relevance to CKD, such as the
underlying GFR levels, proteinuria, serum phosphate,
albumin, and biomarkers of inflammation. Of note, 25D
apart, also phosphate emerged as an independent and strong
predictor of death and renal disease progression, an
observation in keeping with recent data from another
European cohort.27 Although, residual confounding in
observational studies can rarely, if ever, be excluded, our
analysis based on competing risk and updated longitudinal
data — including circulating levels of 1,25D — lends support
to the hypothesis that VD deficiency plays a role in the risk of
progression to dialysis and death in CKD patients. At
variance with studies based on biomarkers, studies based on
genetic polymorphisms related with the same biomarkers are
largely bias free.28 In this respect it is noteworthy that the
Bsm I polymorphism of the vitamin D receptor gene has
been associated with mortality in dialysis patients.29 From a
biological point of view, apart from previously mentioned
studies in parathyroid cells,25 also other cells species, such as
endothelial cells30 and vascular muscle cells31 express 1a-
hydroxylase and may therefore generate 1,25D by an
autocrine pathway. As previously alluded to, it is possible
that, due to limited renal 1a-hydroxylase activity, production
of the active VD form 1,25D, be critically dependent on 25D
availability in CKD patients.
25D was a better predictor of clinical events than 1,25D.
This finding extends to the predialysis phase the observations
in ESRD.2 In this regard it is noteworthy that 1,25D was
inferior to circulating 25D even when used as a time-
dependent covariate. Although various explanations can
account for this phenomenon2 and recognizing that external
validation in other CKD cohorts is needed, our data indicate
that 25D is a better risk marker than 1,25D in CKD.
In the last decade the interference of vitamin D with the
CV system has emerged as one of the most intriguing
research areas in CV medicine. Hypertension, coronary heart
disease, and heart failure have all been linked to vitamin D
deficiency.32 Our study was not powerful enough for testing
the relationship of 25D with CV outcomes such as incident
coronary heart disease and heart failure. Given the high-CV
risk of CKD, the issue deserves to be addressed in well-
powered future studies.
Study limitations
Our study has limitations and strengths. First, it was based on
a relatively small cohort. In this respect, failure to confirm the
association of 1,25D treatment with clinical outcomes14,33,34
may reflect insufficient study power. Second, it was based on
an incident series (that is new referrals to the nephrologist) of
Caucasian patients and therefore our observations may not
apply to other ethnicities. Third, the possibility of residual
confounding cannot be excluded. On the other hand the
longitudinal design and the use of laboratory and clinical
data as time-dependent covariates are elements of methodo-
logical strength.
Conclusion
Assessment of VD status in CKD patients is presently seen as
a step for formulating appropriate treatment of secondary
hyperparathyroidism. Recent data in ESRD2 and the present
study in CKD suggest that measurement of 25D may have
clinical implications beyond guideline recommendations
related to the prevention and control of hyperparathyroid-
ism.20 Ideally, changes in clinical practice should be based on
experiments rather than on observational studies. Thus our
data, rather than implying universal screening for VD
insufficiency or deficiency in CKD, make the need of a
randomized controlled study of diagnosis even more
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compelling (that is, identification of VD deficiency) and
appropriate intervention (for example, cholecalciferol) to
prove a causal relationship between VD deficiency, therapy,
and improved survival in CKD patients.
MATERIALS AND METHODS
Inception cohort and referral pattern
All consecutive patients referred to the outpatient clinic of the
Division of Nephrology at Cremona Hospital in 2002 and 2003 were
recruited. This tertiary care hospital serves a population of
approximately 200,000 residents. To be included in this study,
patients had to be referred for the first time to the nephrologist, be
VD naı¨ve, clinically stable, and with a diagnosis of CKD stages 2–5
without imminent need for dialysis commencement. No patient
suffered from inflammatory diseases, bowel resections, or malab-
sorption, or made use of drugs interfering with 25D absorption.
Baseline data and primary exposures of interest
Data on baseline characteristics, smoking habit, documented
diagnosis of renal disease causes, diabetes, clinical CV diseases,
neoplasm, and history of hypertension were collected at the first
referral and defined based on the International Classification of
Diseases, Ninth Revision. All patients were in stable clinical
conditions and none had acute coronary syndrome or evidence of
CV congestion at the time of enrollment. Blood samples for the
primary exposures of interest (that is, 25D and 1,25D levels) were
collected at the first referral before initiating VD treatment.
Follow-up data and study end points
Patients were seen regularly with frequency dependent on renal
function and comorbid conditions, but usually every 3–6 months. As
per center policy oral calcitriol therapy was started at the initial dose
of 0.25mg/day in presence of PTH 4100 pg/ml or serum calcium
o8.5 mg/100 ml. Dose adjustment was based on serum calcium and
PTH levels with a maximum daily dose of 0.5 mg. Plasma 1,25D as
well as standard laboratory tests were measured at each visit and up
to six repeated measures were obtained from each patient for each of
these tests. The study end points (death and the need for dialysis due
to ESRD) were accurately recorded. To avoid missing data or loss to
follow-up, patients were contacted by telephone in case they missed
any appointment and at the study end date (15 December 2007) if
their last scheduled visit was before November 2007 and if they were
not known to be already on dialysis or died. Each death was
reviewed and assigned an underlying cause by three physicians not
involved in the study, on the basis of all available medical
information. In cases of out-of-hospital deaths, family members
and the general practitioner were interviewed by telephone to
ascertain the circumstances surrounding the death.
Laboratory methods
Blood sampling was performed, after overnight fasting, between
0700 and 0900 hours. After 20–30 min of quiet resting in
semirecumbent position samples were taken into chilled vacutainers,
placed immediately on ice, centrifuged within 30 min at 4 1C and
the serum stored at 80 1C before assay. Levels of 25D were
measured at baseline in duplicate using RIA (Immuno-Diagnostic
System Inc., Fountain Hills, AZ, USA; intra-assay CV 5%; interassay
CV 8%). The precision of the method was identical in the normal
and in low range. All samples were processed in a single assay. Also
levels of 1,25D were measured in duplicate using RIA (DiaSorin Inc.,
Stillwater, MN, USA; CV o7% at levels o30 pg/ml). Glomerular
filtration rate was estimated (eGFR) using the four-variable
modification of diet in renal disease formula.35 Total intact PTH
was measured using IRMA (Scantibodies Laboratory Inc., Santee,
CA, USA; normal range 14–65 pg/ml).
Statistical analyses
Data are expressed as mean±s.d., median, and interquartile range,
or frequencies, as appropriate. Paired relationships were analyzed by
Pearson’s product moment correlation coefficient or Spearman’s
rank correlation coefficient.
The Cox procedure was used to model time to dialysis initiation
and death as a function of baseline 25D and 1,25D levels. A
competing risk model for correlated unordered failure events
stratified by failure type (dialysis or death) was fitted.36 Separate
models of time to each event were run first to ascertain that the
effect of the exposures was the same on both events and identify
possible stratum-specific effects. Covariates considered for adjust-
ment included time-invariant clinical characteristics, baseline eGFR,
and traditional CV risk factors, and time-varying GFR, proteinuria,
serum phosphate, calcium, PTH, C-reactive protein, fibrinogen,
homocysteine, and concomitant therapies, including VD supple-
ment (calcitriol). For both time to each event models and the
competing risk model, separate equations were initially built on 25D
(treated both as continuous and categorical variable) and the
following sets of clinically meaningful covariates: demographics,
comorbid conditions, acute reactive phase products, markers of
kidney function and damage, and therapies. Models including
baseline values of these variables (standard models) were compared
to those built on their time-varying values (time-dependent models)
in terms of fit (Bayesian information criteria and Cox-Snell
residuals) and hazard proportionality. Interaction of the exposure
(25D) with key covariates (for example, CKD stage, PTH,
proteinuria, diabetes, subsequent calcitriol therapy, and age) was
also assessed. Candidate covariates for the final models were
identified from these models. Owing to the relatively low event
number, a manual hierarchical elimination approach37 was followed,
sticking to the power rule of 10—one parameter per 10 events.
Briefly, (1) interaction assessment was based on precision (P40.1);
(2) lower-order components were deleted only after elimination of
their product term; (3) variations of the exposure regression
coefficient were monitored to identify variables that were eligible to
be dropped as nonconfounders (validity over precision rule) and
checking the overall model fit and hazard proportionality. The
survival effect of variables that may (at least partly) be in the causal
chain between kidney function decline and the outcome (for
example, VD levels and phosphate) was studied treating eGFR as
covariate or stratifying variable. Model specification, proportionality
assumption, and overall fit were checked by reestimation, formal
and graphical tests based on residuals, and testing the interaction
with time of the variables in the model. Analyses were performed
using STATA 9.2 SE (Stata Corp., College Station, TX, USA).
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